Gefitinib inhibits the growth of Toxoplasma gondii in HeLa cells
2
조회
0
다운로드
2
인용
0
참고문헌
초록
Toxoplasma gondii is the causative agent of toxoplasmosis with symptoms of congenital neurological and ocular diseases and acquired lymphadenitis, retinochoroiditis, and meningoencephalitis. Small molecules which block the activity of protein kinases were tested in in vitro culture of T. gondii to find new therapeutic drugs of safer and more effective than the combined administration of pyrimethamine and sulfadoxine that sometimes provoke lethal Stevens-Johnson syndrome. Among them, Gefitinib and Crizotinib inhibited intracellular growth of T. gondii in HeLa cells by counting the number of T. gondii per parasitophorous vacuolar membrane whereas Sunitinib did not. Gefitinib inhibited the growth of T. gondii in a dose-dependent manner over 5 microM up to the tolerable concentration of HeLa cells and halted the division of the parasite immediately from the time point of treatment. Gefitinib inhibition suggests that tyrosine kinases of EGFR family or other homologous kinases of the parasite itself may be the target to cause the block of T. gondii growth.
Abstract
Toxoplasma gondii is the causative agent of toxoplasmosis with symptoms of congenital neurological and ocular diseases and acquired lymphadenitis, retinochoroiditis, and meningoencephalitis. Small molecules which block the activity of protein kinases were tested in in vitro culture of T. gondii to find new therapeutic drugs of safer and more effective than the combined administration of pyrimethamine and sulfadoxine that sometimes provoke lethal Stevens-Johnson syndrome. Among them, Gefitinib and Crizotinib inhibited intracellular growth of T. gondii in HeLa cells by counting the number of T. gondii per parasitophorous vacuolar membrane whereas Sunitinib did not. Gefitinib inhibited the growth of T. gondii in a dose-dependent manner over 5 microM up to the tolerable concentration of HeLa cells and halted the division of the parasite immediately from the time point of treatment. Gefitinib inhibition suggests that tyrosine kinases of EGFR family or other homologous kinases of the parasite itself may be the target to cause the block of T. gondii growth.
참고문헌 (9)
- John DT, "The tissue coccidia: Toxoplasma gondii. Markell and Voge’s Medical Parasitology", pp.139~149 (2006), Elsevier Inc.
- Choi WY, "Foodborne outbreaks of human toxoplasmosis", J Infect Dis, 175, pp.1280~1282 (1997)
- 박영훈, "Clinical Features of Ocular Toxoplasmosis in Korean Patients", The Korean Journal of Parasitology, 49(2), pp.167~171 (2011), 대한기생충학ㆍ열대의학회
- Wei F, "Protein kinases of Toxoplasma gondii : functions and drug targets", Parasitol Res, 112, pp.2121~2129 (2013)
- Qui W, "Novel structural and regulatory features of rhoptry secretory kinases in Toxoplasma gondii", EMBO J, 28, pp.969~979 (2009)
- Zhang J, "Targeting cancer with small molecule kinase inhibitors", Nature Rev(Cancer), 9, pp.28~39 (2009)
- Garofalo M, "EGFR ad MET receptor tyrosine kinase-altered microRNA expression induces tumorigenesis and Gefitinib resistance in lung cancers", Nature Med, 18, pp.74~82 (2012)
- Cui JJ, "Structure based drug design of Crizotinib(PF-02341066), a potent and selective dual inhibitor of mesenchymal-epithelial transition factor(c-MET)kinase and anaplastic lymphoma kinase(ALK)", J Med Chem, 54, pp.6342~6363 (2011)
- Stanley SA, "Identification of host-targeted small molecules that restrict intracellular Mycobacterium tuberculosis growth", PLoS Pathog, 10, pp.1~16 (2014)